If it transpires that in the 26 months between November 2022 when the phase 3 trial results were first published and now management has not been seriously addressing the price of DCVax-L with NICE, my faith in them will be destroyed.
As far as I am concerned, if that transpires they will have a serious case to answer as to whether or not they are guilty of dereliction of their duty (or whatever the legalese might be).
Prepare yourself for disappointment, my friend.
NICE reimbursement isn't happening for at least 6 months following approval, probably not in 2025.
Market Data 
Markets 
AI
